CDXS
Codexis, Inc.
Biotechnology · Healthcare · United States
1.19
close · 2026-10-30
value
30
cheaper than peers30
quality
18
stronger fundamentals18
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.68× | 90 |
| cash flow yield, 3 years ago | 2.3% | 90 |
| price to book | 3.30× | 51 |
| cash flow yield, latest year | -18.3% | 37 |
| earnings yield, 3 years ago | -42.9% | 34 |
| earnings yield, latest year | -42.0% | 25 |
| cash flow yield, 2 years ago | -43.8% | 22 |
| cash flow yield, 1 year ago | -41.2% | 21 |
| earnings yield, 1 year ago | -74.8% | 18 |
| earnings yield, 2 years ago | -94.1% | 16 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -75.3% | 57 |
| return on equity | -69.4% | 36 |
| revenue growth | -2.7% | 32 |
| debt to equity | 220.2% | 11 |
4 of 4 measures available
Facts
| market cap | $130M |
| free cash flow | $2.1M |
| employees | 146 |
| first trade | 2010-04-22 |
| next earnings | 2026-11-12 |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.50 | -0.89 | -1.12 | -0.51 |
| free cash flow | -$23.8M | -$53.7M | -$57.1M | $3.0M |
| net income | -$44.0M | -$65.3M | -$76.2M | -$33.6M |
| revenue | $70.4M | $59.3M | $70.1M | $138.6M |
| unusual items | -$3.4M | -$165,000 | -$13.3M | -$3.2M |